 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World...

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

Vaxart, Inc. (NASDAQ:VXRT  Free Report)  Equities research analysts at B. Riley issued their Q1 2024 earnings estimates for shares of Vaxart in a research note issued on Wednesday...

Vaxart, Inc. (NASDAQ:VXRT) Expected to Earn Q1 2024 Earnings of ($0.18) Per Share

Vaxart, Inc. (NASDAQ:VXRT  Free Report)  Equities researchers at B. Riley issued their Q2 2024 earnings estimates for shares of Vaxart in a note issued to investors on Wednesday, March...

Research Analysts Offer Predictions for Vaxart, Inc.'s Q2 2024 Earnings (NASDAQ:VXRT)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaxart reports inducement grants under Nasdaq listing rule

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the Company or Vaxart ) today announced that the Compensation Committee of the Board of Directors...

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart (NASDAQ:VXRT  Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus...

Vaxart (NASDAQ:VXRT) Releases  Earnings Results, Beats Expectations By $0.03 EPS

Q4 2023 Vaxart Inc Earnings Call Transcript

Key Financial Highlights and Corporate UpdatesRelated Stocks: VXRT...

Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results

Significant progress made in preparing for a Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study...

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

Vaxart FY 2023 Earnings Preview

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Volume (M)	883,544.00
52-Wk High	$1.59
52-Wk Low	$0.53

VXRT Vaxart Inc

About

Feed

News

Sentiment

Earnings

Fundamentals